



3.2.5 Paediatric Cardiology Research



Publications: 3 | Q1:1

COMPOSITION

Federico Gutiérrez-Laraya Aguado.

Jefe de Servicio de Cardiología Pediátrica. Hospital Universitario La Paz. Profesor Titular. Universidad Francisco de Vitoria.

- **César Abelleiro Pardeiro.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Viviana Arreo del Val.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Antonio Javier Cartón Sánchez.** *Facultativo*

Especialista de Área en Pediatría. Hospital Universitario La Paz

- **Lucía Deiros Bronte.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Marta Gamba Arzoz.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Luis García-Guereta Silva.** *Jefe de Sección de Cardiología Pediátrica. Hospital Universitario La Paz*
- **Carlos Labrandero de Lera.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Álvaro Lafuente Romero.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Diana Salas Mera.** *Médico Adjunto Cardiología Pediátrica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Establishment of Cardiopathy Registers: Creation of comprehensive databases that comply with all legal regulations regarding security, confidentiality, and data protection.
- Advances in Imaging Diagnosis: Innovation and refinement of imaging techniques for precise characterization of pediatric heart diseases.
- Minimally Invasive Diagnostic and Therapeutic Techniques: Development and application of procedures that minimize impact and improve patient recovery.
- Research on Vascular Risk and Environmental Factors: Dedicated studies to understand how environmental factors and lifestyle influence pediatric heart diseases and their prevention.
- Role of Exercise in Pediatric Cardiology: Research on the importance of physical exercise in the detection and treatment of cardiac alterations in children.
- Telemedicine and Cardiac Monitoring: Implementation of telemedicine solutions and the use of IoT devices for efficient and real-time cardiac monitoring.
- Blockchain in Medical Record Management: Application of blockchain technology to ensure the integrity and privacy of medical records.
- Omics Research for Pediatric Cardiology: Search for biomarkers and therapeutic targets through genomic, proteomic, and metabolomic studies.
- Scientific Dissemination and Industrial Collaboration: Publication of research in high-impact journals and collaboration with the pharmaceutical sector for the development of new therapies.
- Creation of Specialized Care Units: Formation of multidisciplinary teams based on the latest research to provide the best care.
- Continuous Training and Public Awareness: Development of educational programs for professionals and families, and collaboration with media to increase the visibility of pediatric heart diseases.

RESEARCH LINES

- Application of Artificial Intelligence and New Technologies: Exploration and adoption of technological advances to enhance the diagnosis, treatment, and monitoring of pediatric heart diseases.
- Innovation in Medical Devices and Pharmacology: Development and assessment of advanced medical devices and new pharmacological compounds tailored to the specific needs of the pediatric population.
- Management of Vascular Risk in Pediatrics: Study and management of vascular risk from the earliest stages of life, focusing on the prevention and early detection of cardiovascular diseases.

RESEARCH ACTIVITY

Publications

- **Cobarro L, Jiménez-Valero S, Gutiérrez-Larraya F, Merino C, Merás P, Ruiz-Cantador J, Balbacid E, Poveda ID, Rosillo SO, Caro-Codón J, Jurado-Román A, Moreno R.** Novel percutaneous aspiration thrombectomy in Fontan conduit obstruction with cardiogenic shock. Case report. *Int J Cardiol Congenit Heart Dis.* 2024; 17: 100518. Letter. IF: 1.2; Q4
- **González-Costello J, Pérez-Blanco A, Delgado-Jiménez J, González-Vilchez F, Mirbet S, Sandeval E, Cuenca-Castillo J, Camino M, Segovia-Cubero J, Sánchez-Salado JC, de la Sota EP, Almenar-Bonet L, Farrero M, Zatarain E, García-Cosío MD, Garrido I, Caballero EB, Gómez-Bueno M, Bagudá JD, Manito-Lorite N, López-Granados A, García-Guereta L, Blasco-Peiró T, Sarraide-Aguayo JA, Sobrino-Márquez M, de la Fuente-Galán L, Crespo-Leiro MG, Coll E, Gran-Ipiña F, Díaz-Molina B, Doñate L, Arribas-Leal JM, Sánchez-Vicario F, Atienza F, Juan-Aracil GR, García-Quintana A, Martínez-Alpuente I, Riesgo-Gil F, Hernández-Montfort J, Oliver-Juan E, Sánchez-Rivas J, Padilla-Martínez M, Pérez-Villares JM, Miñambres E, Domínguez-Gil B.** Review of the allocation criteria for heart transplant in Spain in 2023. *SEC-Heart Failure Association/ONT/SECCE consensus document. Rev Esp Cardiol (Engl Ed).* 2024; 77(1): 69-78. Review. IF: 4.9; Q1
- **Labradero C, Deiros L, Abelleira C, Arreo V, Balbacid EJ, Gutiérrez-Larraya F.** Hemodynamic Monitoring of Pediatric Patients With Heart Failure and Pulmonary Hypertension Using CardioMEMS. *J Soc Cardiovasc Angiogr Interv.* 2024; 3(6): 101933. Article. Not Indexed

Clinical Trial

- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.
Type/Phase: III

Sponsored by: Bristol-Myers Squibb Services Unlimited Company

Signature date: 03/04/2024

- **Labradero de Lera C.** estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética del vericiguat en pacientes pediátricos con insuficiencia cardíaca debido a disfunción sistólica sistémica del ventrículo izquierdo (valor).

Type/Phase: III

Sponsored by: Merck Sharp & Dohme Llc

Signature date: 09/09/2024

- **Gutiérrez-Larraya Aguado F.** abott structural heart device registry (abott sh registry).

Type/Phase: PRODUCTO SANITARIO

Sponsored by: Abbott Medical España S.A.

Signature date: 05/08/2024

- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.

Type/Phase: III

Sponsored by: Bristol-Myers Squibb Services Unlimited Company

Signature date: 12/06/2024

- **García-Guereta Silva L.** estudio retrospectivo, multicéntrico e internacional para describir la evolución natural de la enfermedad de danon.

Type/Phase: No EPA

Sponsored by: Oracle France S.A.S.

Signature date: 12/07/2024

- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.

Type/Phase: III

Sponsored by: Bristol-Myers Squibb Services Unlimited Company

Signature date: 19/12/2024

